Cancer Genomics and Diagnostics: Northeast Indian Scenario

Kundu, Sharbadeb; Das, Raima; Laskar, Shaheen; Choudhury, Yashmin; Ghosh, Sankar Kumar

doi:10.1007/978-981-16-4752-9_24

Cited by 2 publications

(2 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MINT1, MINT31, MINT2, p16, and MLN1 are common CpG island mythelator phenotype (CIMP) markers. 47 , 48 The involvement of CIMP in colon cancer is depicted in Figure 2 .…”

Section: Carcinogenesis: Mechanism Of Colon Cancermentioning

confidence: 99%

Recent Advancements, Limitations, and Future Perspectives of the use of Personalized Medicine in Treatment of Colon Cancer

Dey

Mitra

Pathak

et al. 2023

Technol Cancer Res Treat

View full text Add to dashboard Cite

Due to the heterogeneity of colon cancer, surgery, chemotherapy, and radiation are ineffective in all cases. The genomic profile and biomarkers associated with the process are considered in personalized medicine, along with the patient's personal history. It is based on the response of the targeted therapies to specific genetic variations. The patient's genetic transcriptomic and epigenetic features are evaluated, and the best therapeutic approach and diagnostic testing are identified through personalized medicine. This review aims to summarize all the necessary, updated information on colon cancer related to personalized medicine. Personalized medicine is gaining prominence as generalized treatments are finding it challenging to contain colon cancer cases which currently rank fourth among global cancer incidence while being the fifth largest in total death cases worldwide. In personalized therapy, patients are grouped into specific categories, and the best therapeutic approach is chosen based on evaluating their molecular features. Various personalized strategies are currently being explored in the treatment of colon cancer involving immunotherapy, phytochemicals, and other biomarker-specific targeted therapies. However, significant challenges must be overcome to integrate personalized medicine into healthcare systems completely. We look at the various signaling pathways and genetic and epigenetic alterations associated with colon cancer to understand and identify biomarkers useful in targeted therapy. The current personalized therapies available in colon cancer treatment and the strategies being explored to improve the existing methods are discussed. This review highlights the advantages and limitations of personalized medicine in colon cancer therapy. The current scenario of personalized medicine in developed countries and the challenges faced in middle- and low-income countries are also summarized. Finally, we discuss the future perspectives of personalized medicine in colon cancer and how it could be integrated into the healthcare systems.

show abstract

“…MINT1, MINT31, MINT2, p16, and MLN1 are common CpG island mythelator phenotype (CIMP) markers. 47 , 48 The involvement of CIMP in colon cancer is depicted in Figure 2 .…”

Section: Carcinogenesis: Mechanism Of Colon Cancermentioning

confidence: 99%

Recent Advancements, Limitations, and Future Perspectives of the use of Personalized Medicine in Treatment of Colon Cancer

Dey

Mitra

Pathak

et al. 2023

Technol Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…As per the study by the international league of nations against rheumatism, a communityoriented program for control of rheumatic disease (ILAR COPCORD), in Biguvan village of India, the prevalence of gout is 0.12%. A study made in Vellore showed that the Indian urban population is more prone to gout than the rural population, and 15.8% of the affected patients are less than 30 years of age 4 .…”

mentioning

confidence: 99%

Untitled

2023

IJPSR

View full text Add to dashboard Cite

Gouty arthritis, an inflammatory joint disease, occurs due to the accumulation of Monosodium Urate (MSU) crystals in the joints, mainly at the metatarsophalangeal joints of the big toe. At present, the incidence and prevalence of gout are increasing globally. The various risk factors are responsible for the development of gouty arthritis, including nonmodifiable, modifiable, and genetic factors. Under physiological conditions, the purine undergoes a catabolic pathway to produce the uric acid end product excreted from the body using various uric acid transporters. The overproduction or underexcretion of uric acid leads to the pathophysiology of hyperuricemia and promotes the MSU crystals formation and deposition in joints to trigger inflammation by releasing inflammatory mediators in gouty arthritis. If chronic gout has been left untreated, the pain worsens and eventually causes cartilage degradation, bone erosion, and urolithiasis. The research studies of the antigout activity of the various secondary metabolites are manifested in this review. The inflammatory pathways involved in gouty arthritis development are being discussed to find a new therapeutic target to treat gouty arthritis better. INTRODUCTION:In the 13 th century, Randolphus of bocking was the first person who coined the term "GOUT" which is derived from the Latin word "GUTTA" (which translates into "drop"). In the olden days the disease was believed to be caused by drops of viscous hum or (liquid) dripping from the blood into the joints, this explanation currently resembles the modern scientific explanation 1 . Gouty arthritis is a type of arthropathy in which joints are painful due to the accumulation of monosodium urate crystals. It usually affects the big toe (metatarsal joint). It can also affect other joints like the ankle, knee, foot,

show abstract

Cancer Genomics and Diagnostics: Northeast Indian Scenario

Cited by 2 publications

References 44 publications

Recent Advancements, Limitations, and Future Perspectives of the use of Personalized Medicine in Treatment of Colon Cancer

Recent Advancements, Limitations, and Future Perspectives of the use of Personalized Medicine in Treatment of Colon Cancer

Untitled

Contact Info

Product

Resources

About